Patents by Inventor J. Donald Capra

J. Donald Capra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8563305
    Abstract: High efficient methods for producing an antibody molecule that binds an antigen are described. The methods include obtaining a population of PBMC enriched for CD19highCD3negCD20low to negCD38highCD27high cells from a mammal exposed to an antigen from sample of cells enriched for PBMC. The cells are isolated from a sample obtained at a time that the fraction of PBMC expressing antibody reactive to the antigen is at a high level. Sequences encoding heavy and light chain variable domains are prepared in a manner that allow production of molecules with natural heavy and light chain pairing.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: October 22, 2013
    Assignees: Oklahoma Medical Research Foundation, Emory University
    Inventors: Rafi Ahmed, Joseph Miller, Patrick C. Wilson, J. Donald Capra, Jens Wrammert
  • Patent number: 6673342
    Abstract: Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: January 6, 2004
    Assignees: Bond of Regents, The University of Texas System, The United States of America as represented by the Department of Health and Human Services
    Inventors: J. Donald Capra, Jonathan M. Hexham, Leon N. Carayannopoulos, Edward E. Max
  • Patent number: 6303339
    Abstract: The present disclosure relates to DNA sequences encoding one or more antigenic epitopes of the Ro 60 kD autoantigen, as well as to antigenic peptides themselves which correspond antigenically to epitopes found on the Ro/SS-A ribonucleoprotein (RNP) particle. Peptides which incorporate the antigenic epitopic core sequences disclosed herein may be employed in place of the Ro/SS-A RNP in any of a variety immunoassays including ELISA assays. The polypeptides of the invention may be employed in colorimetric assays for the identification and characterization of autoimmune diseases such as systemic lupus erythematosus (SLE) and Sjogren's syndrome. The DNA sequences disclosed herein may be employed in the preparation of the 60 kD Ro antigen, peptides which incorporate antigenic core sequences thereof, to probe for Ro sequences by hybridization analysis, and the like.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: October 16, 2001
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard D. Sontheimer, Tsu-San Lieu, Daniel P. McCauliffe, J. Donald Capra
  • Patent number: 6063905
    Abstract: Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: May 16, 2000
    Assignees: Board of Regents, The University of Texas System, The United States of America as represented by the Department of Health and Human Services
    Inventors: J. Donald Capra, Jonathan M. Hexham, Leon N. Carayannopoulos, Edward E. Max
  • Patent number: 5580759
    Abstract: An exonuclease-based method for joining and/or constructing two or more DNA molecules. DNA fragments containing ends complementary to those of a vector or another independent molecule were generated by the polymerase chain reaction. The 3' ends of these molecules as well as the vector DNA were then recessed by exonuclease activity and annealed in an orientation-determined manner via their complementary single-stranded regions. This recombinant DNA may be transformed directly into bacteria without a further ligase-dependent reaction. Using this approach, recombinant DNA molecules are constructed rapidly, efficiently and directionally. This method can effectively replace conventional protocols for PCR cloning, PCR SOEing, DNA subcloning and site-directed mutagenesis.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: December 3, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventors: Yih-Sheng Yang, Philip W. Tucker, J. Donald Capra